EFSA completed its first full risk assessment of BPA in 2006. Since then, the Authority and its scientific panels have considered hundreds of scientific publications in peer-reviewed scientific journals as well as reports from studies submitted by industry. EFSA reviewed new scientific information on BPA in 2008, 2009, 2010, 2011 and 2016. Its comprehensive re-evaluation was published in January 2015.
2016 - EFSA evaluates new scientific evidence on the potential effects of BPA on the immune system following publication of a report by the Dutch National Institute for Public Health and the Environment, which raises concerns about the effects of BPA on the immune system of fetuses and young children.
2015 – EFSA’s most recent review of BPA exposure and toxicity concludes that BPA poses no health risk to consumers of any age group (including unborn children, infants and adolescents) at current exposure levels.
2014 - EFSA presents the second part of its draft opinion relating to the human health risks posed by exposure to BPA, accompanied by an eight-week public consultation.
2013 - EFSA holds a public consultation on the first part of its draft scientific opinion, specifically on its assessment of consumer exposure to BPA. EFSA provisionally concludes that for all population groups diet is the major source of exposure to BPA and exposure is lower than previously estimated by EFSA.
2012 - EFSA’s experts decide to do a full re-evaluation of the human risks from exposure to BPA in the diet, also taking into consideration of non-dietary sources in overall exposure to BPA. The review is to include all the available data and scientific studies on dietary exposure published since 2006 and further evaluation of the possible relevance to human health of some BPA-related effects observed in rodents at low dose levels.
2012 - EFSA tackles the issue of low dose effects in toxicology and risk assessment at its dedicated Scientific Colloquium, with the participation of international experts, taking place in Parma in June.
2011 - EFSA addresses reports on BPA published by the French Health and Safety Agency (ANSES) in September 2011. The experts consider overall that the report on health effects of BPA does not change the views expressed by the Panel in its earlier opinions on the safety of BPA. Following an exchange of information, EFSA and ANSES conclude that ANSES’ work was limited to hazard identification while EFSA had carried out a full risk assessment of BPA in 2006.
2010 - EFSA updates its advice on BPA in September 2010 following a comprehensive review of then recent scientific literature and studies on BPA toxicity at low doses. The CEF Panel conclude they cannot identify any new evidence which would lead them to revise the TDI for BPA of 0.05 mg/kg body weight set by EFSA in its 2006 opinion. The available data do not provide convincing evidence of neurobehavioural toxicity of BPA. One Panel member expressed a minority opinion, considering that some recent studies pointed to uncertainties regarding adverse health effects below the level used to determine the current TDI.
2010 - EFSA receives a request from the Commission to take into account any new scientific evidence available that might affect the conclusions of the previously adopted opinions on BPA and to liaise closely with EU Member State risk assessment bodies on this issue.
2009 - EFSA assesses a new study by Stump on possible neurodevelopmental effects of BPA. The study had been commissioned by the American Chemistry Council to address safety concerns raised by the Canadian government, which had introduced legislation to ban the use of polycarbonate in baby feeding bottles.
2008 - EFSA addresses the differences in the ability of infants and adults to clear BPA from the body. EFSA confirms that exposure to BPA is well below the then TDI of 0.05 mg/kg bw for both adults and newborns. After exposure to BPA the human body rapidly metabolises and eliminates the substance. This is also true for newborns who can clear BPA at levels far in excess of the TDI.
2008 - EFSA assesses a study by Lang et al. that suggested a link between levels of urinary BPA and increased occurrence of heart disease and diabetes. EFSA notes that the study does not include information on long-term exposure to BPA which would be needed to establish a correlation between BPA and the development of the chronic medical conditions in question.
2006 - EFSA completes its first full risk assessment of BPA in 2006 and set a Tolerable Daily Intake (TDI) of 0.05 milligrams/kilogram of body weight (mg/kg bw/day) for this substance. At the same time, EFSA also evaluates intakes of BPA through food and drink, for adults, infants and children and finds that they are all below the TDI.